[A20-66] Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 26.01.2021
Project no.:
A20-66
Commission:
Commission awarded on 27.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Indication:
| Adults with active axial spondyloarthritis in 3 subindications with inadequate response or intolerance to prior therapies |
Result of dossier assessment:
| Added benefit not proven for any of the 3 research questions |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-14 | Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-65 | Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G20-32 | Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66 | Commission completed |
Federal Joint Committee (G-BA)
2021-01-26: A G-BA decision was published.